Physician profile
Stephen A Besson
NPI 1750344552
$11,740.30
in general payments reported to CMS, 2019-2025
59 companies · $1,418 in 2025
The $1,418 reported for 2025 was more than what 90% of Adolescent Medicine (Internal Medicine) providers received nationally (typical 2025 total: $165).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,124 · 2020: $1,641 · 2021: $1,899 · 2022: $2,008 · 2023: $1,141 · 2024: $1,510 · 2025: $1,418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,053 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,052.85 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,195.45 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $925.52 | 2019-2025 | Farxiga, Airsupra, Fasenra |
| Pfizer INC. | $868.11 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $801.09 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $684.34 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $629.40 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $616.34 | 2021-2025 | |
| Lilly USA, LLC | $614.27 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $597.25 | 2019-2024 | Trelegy Ellipta |
| Sumitomo Pharma America, INC. | $561.34 | 2023-2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $516.16 | 2020-2025 | Verquvo, Vaxneuvance, Gardasil 9 |
| Abbvie INC. | $494.27 | 2021-2025 | Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $491.49 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Allergan, INC. | $340.22 | 2019-2020 | |
| Mylan Specialty L.P. | $309.63 | 2019-2024 | Yupelri |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Besson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.